News - Page 3
Newcells Biotech collaborates with consortium in Eurostars funded project to advance novel therapy for Alpha-1 Antitrypsin (AAT) Deficiency
The Eurostars grant of €1.2m will support the partners, led by Gain, and includes Newcells, the Institute for Research in Biomedicine (Lausanne) and the University of Helsinki. Newcells will…
Read update
The latest FMT Assay: An invaluable tool for modelling fibrotic disease
Fibrotic diseases, including liver fibrosis, pulmonary fibrosis, and renal fibrosis, are characterized by the excessive deposition of extracellular matrix (ECM) components, leading to the formation of fibrous tissue that…
Read update
New Product Launched – aProximate™ 96-well Assay-Ready Plates
Get our aProximate™ PTCs to your lab anywhere in the world (24 & 96-well plates) aProximate™ Assay-ready plates contain freshly isolated primary human proximal tubule cells (PTCs). The plates are…
Read update
Newcells team support charity with festive jumpers
Thursday 8th December 2022 was Christmas Jumper Day in the UK to raise money for the charity Save the Children. A prize was given for the…
Read update
NB staff supports Motor Neurone Disease Charity
Having become engaged (now married!) in the summer of 2021, Will’s thoughts turned to arrangements for his stag party. Rather than take the traditional route Will hatched a plan…
Read update
How a glomerulus in vitro model can accelerate drug development
The glomerulus is the part of the kidney involved in the filtration of solutes and waste from the blood. Damage to the glomerulus by diabetes mellitus, hypertension, glomerulonephritis, or…
Read update
New Product Launched – aProximate™ Assay-Ready Plates for transporter studies
aProximate™ Assay-ready plates contain freshly isolated primary human proximal tubule cells (PTCs). The plates are provided in an easy to use 24-well Transwell® format. Visit our product page…
Read update
Gene therapy vectors: Preclinical testing with retinal organoids
Adeno Associated Virus (AAV) vectors have emerged as the most successful retinal gene therapy vectors following the FDA approval of Luxturna in 2017. This new gene therapy product is…
Read update
Organ-on-a-chip: the next generation tool for drug development?
Organ-on-a-chip (OoC) or Microphysiological systems (MPS) are microfluidic devices providing a controlled microenvironment for miniaturised tissues mimicking physiological architecture and function of human tissues and organs. The application of dynamic…
Read update
Retinal Organoids for Drug Discovery
Retinal diseases have been at the forefront of gene and cell therapy over the last 30 years with conditions such as macular degeneration and Stargardt disease likely to be…
Read update
Why is an in vitro model of the glomerulus desperately needed?
In most cases, once the kidney’s function is limited, the only treatment options are dialysis and kidney transplant. The absence of effective drugs to treat kidney disease is partly…
Read update
How to reduce drug attrition during drug development?
There are two main causes of drug attrition: safety and efficacy, and in both instances, the common denominator is the inadequacy of current preclinical models to predict outcomes in…
Read update
